FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

NCT06519370 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: FDA018-ADC
DRUG: Eribulin
DRUG: Capecitabine
DRUG: Gemcitabine
DRUG: Vinorelbine

Sponsor

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.